Overview

Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma

Status:
Withdrawn
Trial end date:
2006-11-01
Target enrollment:
0
Participant gender:
All
Summary
This study will determine the response rate of daily low dose interferon-alpha-2b in patients with metastatic or unresectable clear cell renal cell carcinoma.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Ohio State University Comprehensive Cancer Center
Treatments:
Interferon alpha-2
Interferon-alpha
Interferons
Criteria
Inclusion Criteria:

- Metastatic or unresectable clear cell renal cell carcinoma

- Measurable disease

Exclusion Criteria:

- Prior interferon therapy

- More than 3 prior therapy regimens